title: Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease.
abstract: The role of T cell immunity in virus control during chronic infection was examined in 79 human immunodeficiency virus type 1 (HIV-1)-infected subjects randomized to receive antiretroviral therapy. HIV-1 p24-specific responses were detected in 20% of the subjects at baseline, increasing to 28% of the subjects at weeks 16-24. Induction of virologic suppression was associated with lower plasma HIV-1 RNA levels and a higher percentage of Fas+ CD8+ T cells at baseline, whereas maintenance of suppression was associated with higher CD4+ T cell counts and, marginally, with a higher percentage of Fas+ CD4+ T cells at weeks 16-24. These findings indicate that Fas coexpression on T cells, in addition to plasma HIV-1 RNA levels and CD4+ T cell counts, may predict virologic outcome.
authors.affiliation: Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98109, USA. uma@u.washington.edu
authors.forename: Uma
authors.initials: U
authors.lastname: Malhotra
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Bosch
authors.forename: Ellen
authors.initials: E
authors.lastname: Chan
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Fischl
authors.forename: Ann C
authors.initials: AC
authors.lastname: Collier
authors.forename: M Juliana
authors.initials: MJ
authors.lastname: McElrath
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000382:microbiology; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D010641:Phenotype; D011446:Prospective Studies; D013601:T-Lymphocytes / Q000276:immunology* / Q000382:microbiology*; D019562:Viral Load; D019014:fas Receptor / Q000032:analysis
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D017320:HIV Protease Inhibitors; D019014:fas Receptor